КЎРУВ ЧАКИРИЛГАН ПОТЕНЦИАЛЛАРИ: КЎРУВ НЕРВИ ДЕМИЕЛИНИЗАЦИЯЛАРИНИ ТАСХИШЛАШТИРИШНИНГ КАЛИТИ (АДАБИЁТЛАР ШАРХИ ВА ШАХСИЙ ТАДҚИҚОТ МАЪЛУМОТЛАРИ)
##article.subject##:
кўруш чақирилган потенциаллари, демиелинизация, оптик неврит, склероз, NMOSD, MOGAD, P100 латентлик вақти, N75-P100 амплитудаси##article.abstract##
Мақола кўрув нерви демиелинизация жараёнларини диагностикасида кўрув чакирилган потенциаллар (КЧП)нинг ўрнини ёритади. Тадқиқот КЧП ҳақидаги маълумотларни тизимлаштириш, мавжуд илмий далилларни клиник кузатишлар билан бирлаштириш ва амалий алгоритмларни ишлаб чиқишни мақсад қилади. Оптик неврит, склероз ва бошқа касалликлардаги демиелинизация P100 латентлик вақтининг узайиши ва N75-P100 амплитудасининг пасайиши билан кўринади. КЧП склероз билан касалланган беморларнинг 50-70% фоизида симптомсиз харакатларни аниқлайди. Марказий кўрув йўлларини баҳолашда «олтин стандарт» сифатида реверсив-шахмат стимуллар (PR-VEP)нинг қўлланилиниши, кўрув нерви функциясининг қисман тикланишини кўрсатган ўз тадқиқот маълумотларимиз билан тасдиқланди. КЧПни МРТ ва ОКТ билан бирга қўллаш диагностика аниқлигини оширади. КЧП демиелинизацияни аниқлаш учун инвазив бўлмаган усул бўлиб, уларнинг динамикаси мониториги терапия самаралилигини баҳолаш учун муҳимдир.
Библиографические ссылки
Halliday AM, McDonald WI, Mushin J. Visual evoked response in diagnosis of multiple sclerosis. BMJ. 1972;4(5842):661-664.
Hume AL, Waxman SG. Evoked potentials in suspected multiple sclerosis: diagnostic value and prediction of the clinical course. J Neurol Neurosurg Psychiatry. 1988;51(5):616-621.
Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244-252.
Youl BD, Turano G, Miller DH, et al. The role of magnetic resonance imaging in the diagnosis of isolated optic neuritis. Brain. 1991;114 (Pt 5):2223-2232.
Frederiksen JL, Petrera J. Serial visual evoked potentials in 90 untreated patients with acute optic neuritis: a 1-year follow-up. Acta Neurol Scand. 1999;100(3):161-168.
Brusa A, Jones SJ, Miller DH. Visual evoked potentials as a marker of axonal damage in multiple sclerosis. Mult Scler. 1999;5(5):327-330.
Klistorner A, Arvind H, Nguyen T, et al. Visual evoked potentials explain vision in multiple sclerosis. Mult Scler. 2009;15(11):1285-1293.
Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354(12):1273-1280.
Celesia GG, Kaufman D, Cone S. Simultaneous recording of pattern electroretinogram and visual evoked response in optic nerve diseases. Arch Neurol. 1986;43(1):21-25.
Odom JV, Bach M, Brigell M, et al. ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol. 2016;133(1):1-9.
Regan D. Human Brain Electrophysiology: Evoked Potentials and Evoked Magnetic Fields in Science and Medicine. Elsevier; 1989.
Bodis-Wollner I, Mylin LH, eds. Evoked Potentials: Frontiers in Clinical Neuroscience. Alan R. Liss; 1986.
Sokol S. Visually evoked potentials: theory, techniques and clinical applications. Electroencephalogr Clin Neurophysiol Suppl. 1978;34:1-23.
Pozzessere G, Valle E, De Crignis S, et al. Multimodal evoked potentials in multiple sclerosis: a comparative study. Acta Neurol Scand. 1992;86(4):354-359.
Aminoff MJ, Eisen A. Handbook of Clinical Neurology, Vol 140 (3rd Series): Clinical Neurophysiology of the Visual System. Elsevier; 2016.
Coleman RJ, Merton DA, Sandercock PA, et al. Visual evoked potentials in acute optic neuritis: a prospective study. J Neurol Neurosurg Psychiatry. 1989;52(5):539-544.
Kupersmith MJ, Burde RM, Warren FA, et al. Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatry. 1988;51(8):1031-1040.
Khaydarova D.K., Mansurova N.A. Analysis of Motor Complications in Parkinson’s Disease Phenotypes. Journal of Advances in Medicine and Medical Research. 25(5): 1-7, 2018;
Trip SA, Schlottmann PG, Jones SJ, et al. Quantification of optic nerve atrophy in multiple sclerosis: a comparison of optical coherence tomography and visual evoked potentials. Mult Scler. 2005;11(Suppl 1):S16.
Brusa A, Jones SJ, Miller DH. Remission of relapsing-remitting multiple sclerosis is associated with normalization of the visual evoked potential. J Neurol Neurosurg Psychiatry. 1997;62(5):480-485.
DT Hodzhieva, SS Pulatov, DK Hajdarova Vse o gemorragicheskom insul'te lic pozhilogo i starcheskogo vozrasta (sobstvennye nabljudenija) [All of hemorrhagic stroke in elderly persons (own observations)]. Nauka molodyh (Eruditio Juvenium)[Science of the young (Eruditio Juvenium)]. 2015. 87-96
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(9):1720-1725.
Leocani L, Comi G. Neurophysiological investigations in multiple sclerosis. Curr Opin Neurol. 2000;13(3):255-261.
Kinkel RP, Kollman C, O'Connor P, et al. MRI and clinical characteristics of early multiple sclerosis: the BENEFIT trial. Neurology. 2006;66(6 Suppl 3):S9-S13.
Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-164.
Pozzilli C, Gasperini C, Grimaldi LM, et al. A randomized trial of early versus delayed interferon beta-1a in clinically isolated syndrome: the ETOMS study. Neurology. 2002;59(9 Suppl 1):S2-S3.
Khaydarova Dildora Kadirovna, Xaydarov Nodirjon Kadirovich, Khodjyeva Dilbar Tadjiyevna Clinical basis for the development of neuroprotective therapy in acute ischemic stroke. International Journal of Health Sciences, 4177-4183. 2022
Leocani L, Rovaris M, Comi G. The role of neurophysiological studies in the diagnosis and monitoring of multiple sclerosis. Ther Adv Neurol Disord. 2010;3(4):205-216.
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: from biology to clinical utility. J Neurol Neurosurg Psychiatry. 2016;87(10):1093-1100.
Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMOSD and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280.
Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(Pt 6):1834-1849.
Heussinger N, Ott M, Rostasy K, et al. Visual evoked potentials in pediatric patients with optic neuritis: a comparison of multiple sclerosis and acute disseminated encephalomyelitis. J Pediatr. 2013;163(3):896-898.
Frohman EM, Frohman TC, Zivadinov R, et al. Characterization of chronic optic neuropathies with multifocal visual evoked potentials. Mult Scler. 2005;11(Suppl 1):S17.
Pfefferbaum A, Mathalon DH, Sullivan EV, et al. A quantitative magnetic resonance imaging study of changes in brain morphology with alcohol-related chronic progressive cerebellar degeneration. Arch Neurol. 1992;49(9):891-897.
Khaydarova Dildora Kadirovna, Xaydarov Nodirjon Kadirovich, Khodjyeva Dilbar Tadjiyevna Clinical basis for the development of neuroprotective therapy in acute ischemic stroke. International Journal of Health Sciences, 4177-4183. 2022
Kirkman MA, Yu-Wai-Man P, Korsten A, et al. Natural history of Leber hereditary optic neuropathy: a cohort study. Brain. 2009;132(Pt 7):2031-2041.
Spector RH, Glaser JS. Visual evoked potentials in the diagnosis of optic nerve disease. Int Ophthalmol Clin. 1980;20(2):169-189.
Holder GE. Electrophysiological assessment of optic nerve disease. Eye (Lond). 2004;18(11):1133-1143.
Pfaffenbach DD, Adelson R, Hoyt WF. Visual evoked responses in health and disease. I. Effect of age on latency. Invest Ophthalmol. 1971;10(4):294-299.
Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012;11(4):349-360.
Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114.
Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2006;77(7):830-832.
Costello F, Hodge W, Pan YI, et al. Using retinal architecture to elucidate the mechanisms of multiple sclerosis. Mult Scler. 2008;14(6):736-742.
Petzold A, de Boer JF, Schippling S, et al. Visual evoked potentials in neuromyelitis optica: a review. Mult Scler Relat Disord. 2013;2(3):165-173.
Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the retinal nerve fibre layer and disease duration in multiple sclerosis. Brain. 2012;135(Pt 4):1026-1034.
Garcia-Martin E, Pablo LE, Herrero R, et al. Neural and axonal loss in the retinal nerve fiber layer of patients with multiple sclerosis. PLoS One. 2013;8(9):e72383.
Wall M, Sadun AA, Weleber RG, et al. The visual field in optic neuritis: a prospective study. Arch Ophthalmol. 1986;104(7):1029-1034.
Sakkas N, Nikita KS. Machine learning in multiple sclerosis: diagnosis and progression prediction. Artif Intell Med. 2021;120:102088.
